Supplementary Figure 5 from MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide

Supplementary Figure 5. A, Colony formation assay on WM98.1 clones expressing an empty vector (vector) or MGMT (MGMT) treated with TMZ with or without veliparib (ABT). B, GI50s of the same WM98.1 clones treated with MMS with our without olaparib veliparib. PF50 values are also shown. D, GI50s of the 10 melanoma cell lines treated with MMS with our without olaparib veliparib. PF50 values are also shown. E, MGMT in vitro activity assays. Recombinant MGMT was incubated with increasing concentrations of olaparib, veliparib or lomeguatrib